An interventional study of pulsed-field ablation in Persistent Atrial Fibrillation and Pulsed-field Ablation, sponsored by České Budějovice Hospital. Completed at 3 sites in Czechia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by České Budějovice Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Atrial Fibrillation with a site in Czechia — 39 open to participants now, 50 under way, 6 of them phase 3. Atrial Fibrillation · Czechia.
Among the 184 studies in Atrial Fibrillation with a site in Czechia, this one is the 39th largest by enrollment of the 153 interventional ones that give a count, is one of 15 that started in 2023, is one of 96 with no phase, and was the 145th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →39 of the 184 studies in Atrial Fibrillation with a site in Czechia are open now. Recruiting first, the newest first:
Mitera Hospital · Sites in Czechia, Croatia, Greece and 5 more countries
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18–80
Motol and Homolka University Hospital · Sites in Czechia
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Czechia, United States, Australia and 3 more countries
Ages 18+
Pulse Biosciences, Inc. · Sites in Czechia
Ages 18–85
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 38 · Phase 4 10
First in 1999; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 518 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 153 interventional studies, 540 across the 29 observational. Of the 125 that completed or were terminated, 62 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 184 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with České Budějovice Hospital as lead sponsor.
České Budějovice Hospital has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
13 of the studies in Atrial Fibrillation with a site in Czechia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07210151LUMA Vision Ltd.Anatomical Navigation for Guided Electrophysiology in AFL and AFib | 2026-12-16 |
| NCT06529978CoreMap Inc.Endocardial Mapping With the CoreMap EP Mapping System | 2026-12-31 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT06510556Boston Scientific CorporationFeasibility Study of the FARAFLEX Mapping and PFA System | 2027-02-15 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Atrial Fibrillation with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started to appear mandatory. Our project (The PIVCO study) aims to determine a more standardized procedure representing optimal ablation strategy for patients suffering from PsAF using PFA and multielectrode ablation catheters. The central hypothesis is that ablation of the posterior LA wall (PWI), together with mitral and cavotricuspid isthmus ablation added on top of PVI, will be associated with better effects in terms of rhythm control. Given the speed, safety, and ease of standardization of ablation using electroporation, a demonstration of the superiority of either approach could significantly impact the current standard of clinical care.
Purpose Since a new method called pulsed-field ablation (PFA) has emerged, allowing significantly simpler, safer, and faster creation of ablative lesions in paroxysmal AF and PsAF (13), redefining the "optimal" ablation approach started to appear mandatory. Our project (The PIVCO study) aims to determine a more standardized procedure representing optimal ablation strategy for patients suffering from PsAF using PFA and multielectrode ablation catheters. The central hypothesis is that ablation of the posterior LA wall (PWI), together with mitral and cavotricuspid isthmus ablation added on top of PVI, will be associated with better effects in terms of rhythm control. Given the speed, safety, and ease of standardization of ablation using electroporation, a demonstration of the superiority of either approach could significantly impact the current standard of clinical care.
Primary endpoints
(1) The primary endpoint will be a recurrence of AF (or atrial tachycardia, AT) lasting >30 seconds as assessed using repeated 7-day ECG Holter monitoring in patients without anti-arrhythmic drugs (AADs) during the entire post-blanking follow-up, i.e., starting three months after the index procedure. All patients should complete a 12-month follow-up period.
Secondary endpoints
(1) The first recurrence of on-AADs AF/AT lasting >6 minutes during the post-blanking follow-up period (i.e., disregarding all off-AAD episodes). (2) Number of hospitalizations and emergency out-patient visits related to AF/AT recurrence, worsening of heart failure, or other cardiovascular diseases. (3) Number of electrical cardioversions. (4) Proportion of patients on AADs at the end of follow-up. (5) PFA-related complications. (6) Assessment of the quality of life using standardized instruments (AFEQT, EQ5D). (7) Feasibility of achieving a complete block of the mitral isthmus and PWI using PFA (8) Proportion of patients with delayed conduction into LAA after mitral line (9) Number of patients that underwent repeated ablations during follow-up.
Interventions
Procedures that will be performed on the day of admission for ablation:
Catheter ablation strategy
In all patients, ablation will be performed by electroporation (Farapulse system), as recommended, with at least two applications per each ablation spot. Based on the randomization, patients will be treated using two distinct approaches:
Group PVI (Pulmonary vein isolation only)
Group PVI+ (Complex ablation procedure)
Follow-up The following information will be recorded on the day of discharge: Date of hospital discharge after ablation, length of in-hospital stays, early complications of ablation, and medication at the discharge (all antiarrhythmic drugs except beta-blockers will permanently be discontinued at hospital discharge).
Four 7-day Holter ECG monitoring recordings will be done at 3, 6, 9, and 12 months after ablation (in case of recurrence of AF after ablation, standard treatment according to the treating physician's decision, including the possibility of antiarrhythmic medication, electrical cardioversion or repeated ablation, will be applied).
A telephone visit be done at 1, 3, 6, and 9 months after ablation with an inquiry about complications of the ablation procedure, perceived recurrence of AF, use of antiarrhythmic and antithrombotic medication, elective cardioversion, hospitalization, and reasons for it.
An in-office visit will be done 12 months after ablation in the hospital's out-patient department, including an inquiry about complications of the ablation procedure, perceived and documented recurrence of AF, use of antiarrhythmic and antithrombotic medication, elective cardioversion, hospitalization and reasons for it after ablation, physical examination, medication history, ECG, echocardiography and quality of life questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulmonary vein isolation
Device: pulsed-field ablation
Pulmonary vein isolation supplemented by the additional lesions: left atrial posterior wall isolation, mitral and cavotricuspid isthmus lines
Device: pulsed-field ablation
application of pulsed-field energy for pulmonary vein isolation and linear ablations
Atrial fibrillation recurrence
The primary endpoint will be a recurrence of AF (or atrial tachycardia, AT) lasting \>30 seconds as assessed using repeated 7-day ECG Holter monitoring in patients without anti-arrhythmic drugs (AADs) during the entire post-blanking follow-up, i.e., starting 60 days after the index procedure. All patients should complete a 12-month follow-up period.
Time frame: Whole follow-up (up to 3 years)
Atrial fibrillation recurrence on AADs
The first recurrence of on-AADs AF/AT lasting \>60 minutes during the post-blanking follow-up period (i.e., disregarding all off-AAD episodes).
Time frame: Whole follow-up (up to 3 years)
AF burden
AF/AT burden (calculated as total time spent in arrhythmia over total monitoring time during the whole follow-up).
Time frame: Whole follow-up (up to 3 years)
AADs usage
Number of patients using AADs at the end of follow-up.
Time frame: At the last documented follow-up (up to 3 years)
Hospitalization rate
Number of hospitalisations for all reasons and related to AF/AT recurrence, worsening of heart failure, or other cardiovascular diseases.
Time frame: Whole follow-up (up to 3 years)
Cardioversion
Number of electrical or pharmacological cardioversions.
Time frame: Whole follow-up (up to 3 years)
Complications
PFA-related complications: composite of cardiac tamponade requiring drainage, persistent phrenic nerve palsy lasting more than 24 hours, persistent sinoatrial or atrioventricular block lasting more than 24 hours, major serious vascular complications requiring intervention or prolonging hospitalization, stroke or transient ischemic attack, atrioesophageal fistula, worsening of renal functions due to haemolysis, ST segment elevation or depression with hemodynamic instability, acute myocardial infarction or death within 90 days after ablation.
Time frame: Within 90 days after ablation
Atrial Fibrillation Effect on Quality of Life (AFEQT)
Assessment of the quality of life using standardised instrument AFEQT. Three domains and global QoL will be assessed using a calculated score of 0 to 100% (100% = the best quality of life) based on the patient´s response to 20 questions.
Time frame: 12 months following ablation procedure
EuroQol Group questionnaire on quality of life
Assessment of mobility, self-care, pain or discomfort, anxiety or depression by a Likert scale (1-3, 1 = no limitation, 3 = severe limitation) complemented by visual aid score (1-100, the higher score, the better quality of life).
Time frame: 12 months following ablation procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Jul 2026, 37 months.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 37 months is close to that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2026 → Jul 2026 and completion Nov 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.